IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James Ronald Lawter and Stephen J. Comiskey

Serial No.: Continuation of 09/661,836 Art Unit: Not Yet Assigned

Filed: December 4, 2001 Examiner: Not Yet Assigned

For: FORMULATIONS FOR TREATING OR PREVENTING MUCOSITIS

BOX PATENT APPLICATION U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information

Disclosure Statement, including four (4) pages of Form PTO-1449. The documents cited below were cited by or submitted to the Patent Office in Application Serial No. 09/661,836, filed

September 14, 2000, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

Filed: December 4, 2001

INFORMATION DISCLOSURE STATEMENT

Express Mail Label No.: EL 639 985 041 US Date of Deposit: December 4, 2001

U.S. Patents

*			
<u>Number</u>	Issue Date	<u>Patentee</u>	Class/Subclass
3,966,808	06-29-1976	Luciano	260/559
4,961,926	10-09-1990	Gabrilove	424/85.1
5,082,653	01-21-1992	Pan et al.	424/54
5,102,870	04-07-1992	Florine et al.	514/12
5,284,963	02-08-1994	Sum et al.	552/205
5,328,902	07-12-1994	Sum et al.	514/152
5,386,041	01-31-1995	Sum et al.	552/205
5,401,729	03-28-1995	Sum et al.	514/152
5,420,272	05-30-1995	Sum et al.	544/63
5,430,162	07-04-1995	Sum et al.	552/205
5,545,668	08-13-1996	Skubitz et al.	514/561
5,635,489	06-03-1997	Haley	514/21
5,827,840	10-27-1998	Ramamurthy et al.	514/152
5,886,175	03-23-1999	Sum et al.	544/63
5,945,089	08-31-1999	Libin	424/54
5,981,499	11-09-1999	Hau	514/29
6,025,326	02-15-2000	Steinberg et al.	514/2
4			

Foreign Documents

Number	Publication Date	Patentee	Country
WO 94/27579 A1		Ribogene, Inc.	PCT
*		•	
WO 98/18610 A1	05-07-1998	Bernard Van Lengerich	PCT
WO 99/22703 A1	05-14-1999	Lurident Ltd.	PCT
WO 99/45910 A2	09-16-1999	Mucosal Therapeutics LLC	PCT
WO 00/07601 A1	02-17-2000	Advanced Vision Research	PCT

Publications

BARKER, et al., "Oral care with vancomycin paste for reduction in incidence of alphahemolytic streptococcal sepsis," *J Pediatr Hematol Oncol* 17(2):151-55 (1995).

CARTEE, et al., "Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study," *Cytokine* 7(5):471-7 (1994).

CHI, et al., "Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy," *J. Clin. Oncol.* 13(10):2620-28 (1995).

Filed: December 4, 2001

INFORMATION DISCLOSURE STATEMENT

Express Mail Label No.: EL 639 985 041 US

Date of Deposit: December 4, 2001

CUTLER & SCHUBERT, "Patient factors affecting *Helicbacter pylori* eradication with triple therapy," *American Journal of Gastroenterology* 88(4):505-509 (1993).

EPSTEIN & WONG, "The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy," *Int. J. Radiat. Oncol. Biol. Phys.* 28(3):693-98 (1994).

EPSTEIN, et al., "Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy," *Oral Surg. Oral Med. Oral Pathol.* 62(2):145-8 (1986).

EPSTEIN, et al., "Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse," *Int. J. Radiation Oncology Biol. Phys.* 16(6):1571-5 (1989).

Essentials of Medicinal Chemistry John Wiley and Sons, Inc., pp 512-517 (1976).

FACCHINI, et al., "Attivita di flunoxaprofene per uso topico nelle vaginiti aspecifiche. Confronto con meclociclina solfosalicilato," *Minerva Ginecologica* 41(12):609-614 (1989).

FERRETTI, et al., "Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse," *Bone Marrow Transplant* 3(5):483-93 (1990).

FOOTE, et al., "Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis," *J. Clin Oncol.* 12(12):2630-33 (1994).

FRANCESCHI, et al., "Solitary J-pouch ulcer causing pouchitis-like syndrome," Diseases of the Colon and Rectum 29(8):515-517 (1986).

LOPRINZI, et al., "Alleviation of cytotoxic therapy-induced normal tissue damage," Sem. Oncol. 22(2) Suppl. 3:95-97 (1995).

MITSCHER, et al., "Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids," *J. Med. Chem.* 21(5):485-9 (1978).

ROTHWELL & SPEKTOR, "Palliation of radiation-related mucositis," *Special Care in Dentistry* 10(1):21-25 (1990).

SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of periimplant mucosal hyperplasia and mucositis," *Clinical Oral Implants Research* 8(5):427-433 (1997).

Filed: December 4, 2001

INFORMATION DISCLOSURE STATEMENT

Express Mail Label No.: EL 639 985 041 US

Date of Deposit: December 4, 2001

SONIS, 1993b, "Oral Complications in Cancer Therapy," In: *Principles and Practice of Oncology*, De Vitta et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).

Special Care in Dentistry Jan.-Feb, pages 21-25 (1990).

SPIJKERVET, et al., "Chlorhexidine inactivation by saliva," *Oral Surg. Oral Med. Oral Pathol.* 69(4):444-49 (1990).

VERDI, et al., "A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis," *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.* 80(1):36-42 (1995).

WEISDORF, et al., "Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse," *Bone Marrow Transplant* 4(1):89-95 (1989).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Dated: December 4, 2001 HOLLAND & KNIGHT LLP One Atlantic Center

1201 West Peachtree Street, N.E.

Suite 2000

Atlanta, Georgia 30309-3400

404-817-8500

FAX 404-817-0470

www.hklaw.com

Filed: December 4, 2001

INFORMATION DISCLOSURE STATEMENT

Express Mail Label No.: EL 639 985 041 US

Date of Deposit: December 4, 2001

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this paper and any documents referred to as attached or enclosed are being deposited with the United States Postal Service on this date,

December 4, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Express Mail Label No. EL 639 985 041 US, addressed to Box Patent Application, U.S. Patent and Trademark Office, P.O. Box 2327,

Arlington, VA 22202.

Date: December 4, 2001

Kimberly L. Adams

ATL1 #495265 v1